生物标志物界定的FLOT联合纳武利尤单抗在转移性胃食管癌中的获益:II期IKF-AIO-moonlight试验延长随访与免疫炎症标志物
该II期试验扩展随访分析了FLOT联合纳武利尤单抗治疗转移性胃食管腺癌的52例患者,中位随访12.7个月,中位PFS 7.0个月、中位OS 14.6个月。CPS≥1且基线MLR低的患者中位OS达32.3个月,显著优于MLR高者的7.4个月(p=0.044)。低MLR和CPS阳性可识别从该强化方案中特别获益的人群。
要点
- FLOT联合纳武利尤单抗在转移性GEA中mPFS 7.0个月、mOS 14.6个月。
- CPS≥1且低MLR者mOS 32.3个月,优于高MLR者的7.4个月(p=0.044)。
- FLOT+纳武利尤单抗减轻疼痛但降低躯体功能并增加疲乏。
核心结论
- 低基线MLR联合CPS阳性可识别从FLOT+纳武利尤单抗中特别获益的患者,其生存获益可能超过强化治疗的额外负担。
研究设计与样本
- 因C组初始分析疗效显著,对C组(n=52)进行延长随访及亚组分析,包括PD-L1 CPS、NLR和MLR,并预设EORTC QLQ-C30生活质量分析。
主要发现
- C组中位随访12.7个月,FLOT+纳武利尤单抗(n=52)的mPFS为7.0个月,mOS为14.6个月。
- CPS≥1较CPS<1的PFS为7.6 vs 3.9个月(p=0.13),mOS为17.4 vs 10.0个月(p=0.15)。
- 低NLR者mOS 25.5 vs 6.8个月(p=0.088),低MLR者mOS 28.4 vs 8.3个月(p=0.14)。
- CPS≥1且低MLR者mOS 32.3 vs 7.4个月(p=0.044)。
- Cox模型显示印戒细胞组织学、NLR和MLR与生存相关;FLOT+纳武利尤单抗减轻疼痛但降低躯体功能并增加疲乏。
关键数值与推荐
- CPS≥1且低MLR定义FLOT+纳武利尤单抗下生存增强的人群(mOS 32.3 vs 7.4个月,p=0.044)。
临床怎么用
- 在转移性胃食管腺癌姑息治疗中,可结合基线CPS、MLR(及NLR)筛选适合FLOT联合纳武利尤单抗强化免疫化疗的患者。
- 应用该方案时需权衡生存获益与生活质量影响(疼痛减轻但躯体功能下降、疲乏增加)。
以上解读依据论文摘要(全文未开放获取或许可不允许翻译转载)。
原文
BACKGROUND: First-line treatment of PD-L1-positive advanced gastroesophageal adenocarcinoma (GEA) combines doublet 5-FU/platinum with anti-PD1 inhibition. While triplet chemotherapy (FLOT/TFOX) has demonstrated efficacy alone, data on the combination of FLOT with immunotherapy remain sparse. Given the intensity of triplet immunochemotherapy in a palliative setting, selection of eligible patients for this combination is warranted. METHODS: The AIO-STO-0417 trial enrolled 261 patients between November 2018 and February 2022 in five arms (A and A1 mFOLFOX+nivo/ipi; A2 mFOLFOX followed by nivo/ipi; B mFOLFOX or C FLOT+nivo). Extended follow-up and subgroup analysis were conducted for Arm C due to strong efficacy in the initial analysis. Subgroup analyses included PD-L1 (CPS), neutrophil-to-lymphocyte ratio (NLR), and monocyte-to-lymphocyte ratio (MLR). Prespecified quality-of-life analyses used changes in EORTC QLQ-C30 scores. RESULTS: Median follow-up for Arm C was 12.7 months. Patients receiving FLOT + nivo (n = 52) had a mPFS of 7.0 months and mOS of 14.6 months. CPS≥ 1 was associated with numerically longer survival than CPS< 1 (PFS 7.6 vs 3.9 months; p = 0.13; mOS 17.4 vs 10.0 months; p = 0.15). Cox proportional hazard modeling showed an association of signet-ring cell histology, NLR and MLR with survival. Low NLR (mOS 25.5 vs 6.8 months; p = 0.088) and low MLR (mOS 28.4 vs 8.3 months p = 0.14) identified patients with numerically and clinically meaningful longer survival. Combination of CPS≥ 1 and low MLR defined patients with enhanced survival under FLOT + nivo (MLR: mOS 32.3 vs 7.4 months; p = 0.044). Considering quality of life, FLOT + nivo reduced pain but decreased physical functioning and increased fatigue. CONCLUSIONS: Low baseline MLR and positive CPS identified patients with particular benefit from FLOT + nivo that may outweigh the enhanced burden of intensified therapy. TRIAL REGISTRATION: NCT03647969.
引用
- Masetti M, Nieto A, Lorenzen S, et al. Biomarker-defined benefit from FLOT plus nivolumab in metastatic gastroesophageal cancer: Extended follow-up and immune-inflammatory markers of the phase II IKF-AIO-moonlight trial. Eur J Cancer. 2026. PMID: 42777290. doi:10.1016/j.ejca.2026.117037
供执业医师工作参考,不替代临床判断;数值与分级以指南原文为准。